Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two medications: **Paromomycin** is an aminoglycoside antibiotic used to treat intestinal amebiasis (bowel infection caused by parasites) and hepatic coma (a complication of liver disease). It works by killing bacteria and parasites by blocking their ability to create proteins needed for growth and reproduction. In hepatic coma, it kills bacteria that produce ammonia, helping to improve brain function. **Loperamide** is an antidiarrheal medication that works by acting on mu-opioid receptors in the gut to slow down intestinal movement. This allows more time for fluids and nutrients to be absorbed back into the body, making stool less watery and decreasing bowel movement frequency. The combination may be used in cases where both antimicrobial treatment and control of diarrheal symptoms are needed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paromomycin + loperamide.